New Three-Drug cocktail targets Hard-to-Treat lymphoma
NCT ID NCT02992522
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the combination. Researchers will also watch for early signs that the drugs are shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obinutuzumab, venetoclax, and lenalidomide
What this could lead to
If it works, this could point toward a new treatment option for patients with B-cell non-Hodgkin lymphoma that has returned or stopped responding to prior therapy.
What could go wrong
This is a very early Phase I trial with only 22 participants, so it is primarily testing safety and dosing. The combination may cause significant side effects or may not shrink tumors effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States